{"id":420,"date":"2026-08-09T01:00:44","date_gmt":"2026-08-09T01:00:44","guid":{"rendered":"http:\/\/www.imagerie-medicale-95.fr\/pharmacie\/oblenio-lance-un-essai-clinique-pour-un-nouveau-traitement-des-maladies-auto-immunes\/"},"modified":"2026-08-09T01:00:44","modified_gmt":"2026-08-09T01:00:44","slug":"oblenio-lance-un-essai-clinique-pour-un-nouveau-traitement-des-maladies-auto-immunes","status":"publish","type":"post","link":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/oblenio-lance-un-essai-clinique-pour-un-nouveau-traitement-des-maladies-auto-immunes\/","title":{"rendered":"Oblenio lance un essai clinique pour un nouveau traitement des maladies auto-immunes"},"content":{"rendered":"

Oblenio a commenc\u00e9 \u00e0 administrer son traitement<\/a> LBL-051 \u00e0 des patients dans le cadre d\u2019un essai clinique de phase 1a. Ce traitement, appel\u00e9 tri-sp\u00e9cifique, vise \u00e0 \u00e9liminer \u00e0 la fois les lymphocytes B et les plasmocytes, deux types de cellules du syst\u00e8me immunitaire impliqu\u00e9es dans certaines maladies auto-immunes r\u00e9fractaires.<\/p>\n

L\u2019objectif de ce traitement est de permettre une r\u00e9initialisation durable du syst\u00e8me immunitaire, avec la possibilit\u00e9 d\u2019obtenir une r\u00e9mission prolong\u00e9e sans m\u00e9dicament. L\u2019\u00e9tude, ouverte et multicentrique, recrute des patients atteints de diff\u00e9rentes maladies auto-immunes. Elle utilise une administration sous-cutan\u00e9e pour \u00e9valuer la s\u00e9curit\u00e9 du traitement, sa tol\u00e9rance, ainsi que son efficacit\u00e9, notamment sur la r\u00e9duction des lymphocytes B et des plasmocytes et sur certains marqueurs biologiques.<\/p>\n

Ricardo Grieshaber-Bouyer, professeur d\u2019immunologie clinique syst\u00e9mique et responsable de l\u2019unit\u00e9 d\u2019essais cliniques \u00e0 l\u2019universit\u00e9 FAU Erlangen-N\u00fcrnberg, a soulign\u00e9 : \u00ab Les donn\u00e9es pr\u00e9cliniques de LBL-051 montrent une \u00e9limination compl\u00e8te des lymphocytes B et des plasmocytes gr\u00e2ce au ciblage simultan\u00e9 de deux prot\u00e9ines, CD19 et BCMA, avec une lib\u00e9ration minimale de cytokines. Ces r\u00e9sultats laissent penser que LBL-051 pourrait offrir une r\u00e9initialisation compl\u00e8te de l\u2019immunit\u00e9 des lymphocytes B, plus efficace que les traitements ciblant une seule prot\u00e9ine. \u00bb<\/p>\n

Il a \u00e9galement pr\u00e9cis\u00e9 : \u00ab L\u2019Institut Paul Ehrlich (PEI) a autoris\u00e9 une approche innovante pour cet essai de phase 1a, combinant une escalade de dose et une \u00e9valuation rapide tout en garantissant la s\u00e9curit\u00e9 des patients dans plusieurs maladies auto-immunes. \u00bb<\/p>\n

Tapan Maniar, m\u00e9decin-chef d\u2019Oblenio, a expliqu\u00e9 : \u00ab Ce design de l\u2019essai clinique marque une avanc\u00e9e significative dans le d\u00e9veloppement des traitements utilisant des activateurs de lymphocytes T pour les maladies auto-immunes. Cette strat\u00e9gie diff\u00e9renci\u00e9e permettra d\u2019obtenir rapidement des preuves d\u2019efficacit\u00e9 dans des populations o\u00f9 les besoins sont importants. \u00bb<\/p>\n

Il a ajout\u00e9 : \u00ab Nous esp\u00e9rons d\u00e9montrer le potentiel de LBL-051 \u00e0 induire une r\u00e9initialisation immunitaire large et durable, et \u00e0 faire avancer le ciblage simultan\u00e9 des prot\u00e9ines CD19 et BCMA. \u00bb<\/p>\n

Oblenio a r\u00e9cemment pr\u00e9sent\u00e9 ses donn\u00e9es pr\u00e9cliniques lors du congr\u00e8s 2026 de l\u2019Alliance europ\u00e9enne des associations pour la rhumatologie. Gunter Assmann, chef du service de rhumatologie et d\u2019immunologie clinique \u00e0 l\u2019h\u00f4pital universitaire RUB Minden JWK, a d\u00e9clar\u00e9 : \u00ab Les options th\u00e9rapeutiques modifiant l\u2019\u00e9volution des maladies auto-immunes restent limit\u00e9es, laissant de nombreux patients sans r\u00e9ponse aux traitements standards actuels. Compte tenu de ce besoin non couvert, les r\u00e9sultats pr\u00e9cliniques d\u2019Oblenio et son approche centr\u00e9e sur cette solution potentiellement transformatrice font de notre participation \u00e0 cet essai une priorit\u00e9. \u00bb<\/p>\n","protected":false},"excerpt":{"rendered":"

Oblenio a commenc\u00e9 \u00e0 administrer son traitement LBL-051 \u00e0 des patients dans le cadre d\u2019un essai clinique de phase 1a. […]<\/p>\n","protected":false},"author":0,"featured_media":421,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[414],"tags":[],"class_list":["post-420","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelles"],"_links":{"self":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/comments?post=420"}],"version-history":[{"count":0,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/posts\/420\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/media\/421"}],"wp:attachment":[{"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/media?parent=420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/categories?post=420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.imagerie-medicale-95.fr\/pharmacie\/wp-json\/wp\/v2\/tags?post=420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}